Clinical Report: Deep Remission Tied to RA Control
Overview
Patients with rheumatoid arthritis achieving clinical deep remission (CliDR) demonstrated significantly higher rates of sustained remission and lower relapse rates during treatment tapering compared to those meeting less stringent remission criteria. This suggests that deeper remission may provide additional prognostic information for managing RA treatment, potentially influencing treatment strategies.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to significant morbidity if not effectively managed. Achieving remission is a primary goal of treatment, as it correlates with improved long-term outcomes. However, existing remission definitions may allow for residual inflammation, which can impact patient health and treatment decisions, highlighting the need for more stringent criteria like clinical deep remission (CliDR).
Data Highlights
| Group | Sustained Remission Rate at 5 Years | Relapse Rate |
|---|---|---|
| CliDR | 63% | 12/32 |
| Non-CliDR | 38% | 70/113 |
Key Findings
- 63% of patients in the CliDR group maintained sustained remission at 5 years compared to 38% in the non-CliDR group.
- Relapse occurred in 12 of 32 patients in the CliDR group versus 70 of 113 in the non-CliDR group.
- Tapering treatment was associated with an 8.5-fold higher relapse hazard in patients without CliDR.
- The effect of tapering on relapse was significantly lower in the CliDR group, with an interaction hazard ratio of 0.26, indicating a substantial reduction in relapse risk when tapering is considered.
- During periods without tapering, relapse hazard did not differ significantly between CliDR and non-CliDR groups.
- CliDR reflects complete absence of clinically detectable joint inflammation, unlike other remission definitions.
Clinical Implications
Clinicians should consider the depth of remission when evaluating treatment tapering in RA patients, as achieving CliDR may lead to better long-term outcomes and lower relapse rates. This study underscores the importance of using stringent remission criteria to guide treatment decisions, but further research is needed to confirm these findings before altering clinical practices.
Conclusion
The findings indicate that achieving clinical deep remission is associated with improved sustained remission rates and reduced relapse risk during treatment tapering in rheumatoid arthritis patients. However, as this study is observational, further research is needed to confirm these associations and their implications for clinical practice, especially considering the study's limitations.
References
- Author(s)/Org, RMD Open, 2023 -- Deep Remission Tied to RA Control
- Clinical Rheumatology, 2016 -- Newly diagnosed rheumatoid arthritis patients show improvement with a targeted treatment approach: findings from the DREAM registry
- Clinical Rheumatology, 2012 -- Determining the DAS28-ESR Threshold for Remission According to New Boolean Criteria in Tocilizumab-Treated Patients
- Clinical Rheumatology, 2017 -- Characterization and Definition of Sustained Remission in Rheumatoid Arthritis Patients
- Recommendations Management | EULAR, 2026 -- EULAR Recommendations for Management of RA
- Clinical Rheumatology — Long-term Clinical, Functional, and Economic Outcomes in Early Rheumatoid Arthritis Patients Achieving or Not Achieving Early Remission Under a Real-World Treat-to-Target Approach
- EULAR Recommendations for Management of RA
- Three-Year Results of Tapering TNF Inhibitor to Withdrawal
- American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
